Trial Profile
Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Thiotepa (Primary) ; Treosulfan (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TFT 2 Tx
- 18 Aug 2022 Results published in the Bone Marrow Transplantation
- 30 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Primary endpoint (To assess the probability of disease-free survival, defined as being alive and free of relapse at 1 year after 2nd allogeneic PBSCT from unrelated donors after a uniform intensive-RIC conditioning with the TFT regimen and defined GvHD prophylaxis) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.